IBCN annual meeting included a keynote lecture by Dr. Niko Beerenwinkel discussing inferring tumor evolution from single-cell data. Although the majority of work has been done in other cancers (ie.

IBCN annual meeting included a bladder cancer session, featuring a presentation by Dr. Amanda Myers discussing the ...

Undetectable pre-cystectomy ctDNA predicts better pathological outcomes post-radical cystectomy Patients with undetectable pre-cystectomy status demonstrated recurrence-free survival, regardless of ...

ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo ...

Introduction: Lower urinary tract symptoms (LUTSs) are underreported in patients with multiple sclerosis (MS). We aim to define the incidence of LUTSs in patients with MS and their effect on ...

Urothelial carcinoma is a common malignancy affecting the urinary system, with the spectrum of disease encompassing non-muscle invasive, muscle-invasive and metastatic disease. On a background of ...

Medical and surgical advancements have been made in testicular cancer management over the past 50 years. The evolution of practice standards is expected to provide patients benefits in quality of life ...

Darolutamide is an androgen receptor pathway inhibitor (ARPI) used in patients with prostate cancer (PC). In pivotal trials, it has demonstrated a favorable toxicity profile. There are no head-to-head ...

Metastatic hormone-sensitive prostate cancer is currently an incurable disease. Despite a high response rate to androgen-deprivation therapy, most cases progress to castration-resistant disease, the ...

Overactive bladder and its hallmark symptom, urgency, are thought to be multifactorial in pathogenesis. Smoking is a particularly important risk factor to understand because it is modifiable; studies ...

Although localized prostate cancer is relatively indolent, advanced prostate cancer manifests with aggressive and often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify ...